Non-Small Cell Lung Cancer Coverage from Every Angle

Justin F. Gainor, MD, on Non–Small Cell Lung Cancer: Treatment Update on BLU-667

Posted: Monday, June 17, 2019

Justin F. Gainor, MD, of Massachusetts General Hospital, provides an update on the activity and safety of the novel RET inhibitor BLU-667 in the treatment of RET fusion–positive non–small cell lung cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.